Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis

Multiple Sclerosis Journal

Volumn 22, Issue 6, 2016, Pages 830-841

  Miller, Deborah M ^a   Bethoux, Francois ^a   Victorson, David ^b   Nowinski, Cindy J ^b   Buono, Sarah ^b   Lai, Jin Shei ^b   Wortman, Katy ^b   Burns, James L ^b   Moy, Claudia ^c   Cella, David ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Health related quality of life; Multiple sclerosis; Neuro QOL; Patient reported outcomes

Indexed keywords

ADULT; ANXIETY; ARTICLE; COGNITION; CONCURRENT VALIDITY; DEPRESSION; DISEASE SEVERITY; EMOTION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NEUROLOGIC DISEASE ASSESSMENT; NEUROLOGY QUALITY OF LIFE SHORT FORM; PATIENT-REPORTED OUTCOME; PHYSICAL MOBILITY; PROMIS 10-ITEM GLOBAL HEALTH SCALE; QUALITY OF LIFE ASSESSMENT; SLEEP DISORDER; STIGMA; SYMBOL DIGIT MODALITIES TEST; TEST RETEST RELIABILITY; VALIDATION STUDY;

EID: 85016184031     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515599450     Document Type: Article

References (27)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
2. National Institute of Neurological Disorders and Stroke (NINDS). Multiple sclerosis: Hope through research, http://www.ninds.nih.gov/disorders/multiple-sclerosis/detail-multiple-sclerosis.htm (accessed 27 February 2012).
3. Rudick RA, Miller D, Clough JD, et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49: 1237-1242.
4. Chopra P, Herrman H and Kennedy G. Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: An application of the WHO Disability Assessment Schedule II and WHO Quality of Life-BREF. Int J Rehabil Res 2008; 31: 141-149.
5. Miller DM, Kattan MW and Fu AZ. Health-related quality of life assessment in multiple sclerosis. In: Cohen JA and Rudick RA (eds) Multiple sclerosis theraputics. 4th ed. New York: Cambridge University Press, 2011, pp.79-90.
6. Cella D, Nowinski C, Peterman A, et al. The Neurology Quality-of-Life Measurement (Neuro-QOL) initiative. Arch Phys Med Rehabil 2011; 92 (10 Suppl): S28-S36.
7. Cella D, Victorson D, Nowinski C, et al. The Neuro-QOL project: Using multiple methods to develop a HRQOL measurement platform to be used in clinical research across neurological conditions. Qual Life Res 2006; A14: 1353.
8. Miller DM, Nowinski C, Victorson D, et al. The Neuro-QOL project: Establishing research priorities through qualitative research and consensus development. Qual Life Res 2005; 14: 2031.
9. Perez L, Huang J, Jansky L, et al. Using focus groups to inform the Neuro-QOL measurement tool: Exploring patient-centered, health-related quality of life concepts across neurological conditions. J Neurosci Nurs 2007; 39: 342-353.
10. Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Neurology 2012; 78: 1860-1867.
11. Gershon RC, Lai JS, Bode R, et al. Neuro-QOL: Quality of life item banks for adults with neurological disorders: Item development and calibrations based upon clinical and general population testing. Qual Life Res 2012; 21: 475-486.
12. National Institute of Neurological Disorders and Stroke (NINDS). User manual for the Quality of Life in Neurological Disorders (Neuro-QOL) measures, version 1.0, http://www.neuroqol.org/Instruments%20 %20Tools/Neuro-QOL-UserManual.pdf (September 2010, accessed 15 December 2014).
13. Karnofsky DA and Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed.) Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949, pp.199-205.
14. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Psychological Services, 1991.
15. Rabin R and de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-343.
16. Johnson J, Coons S, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998; 13: 421-433.
17. Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res 2009; 18: 873-880.
18. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT Scales). Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
19. Jaeschke R, Singer J and Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
20. Yost KJ, Eton DT, Garcia SF, et al. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 2011; 64: 507-516.
21. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite in predicting disability in relapsing MS. Neurology 2001; 56: 1324-1330.
22. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-139.
23. Benedict RH, Wahlig E, Bakshi R, et al. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005; 231: 29-34.
24. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol 2011; 24: 244-249.
25. Bruce JM, Bruce AS, Hancock L, et al. Self-reported memory problems in multiple sclerosis: Influence of psychiatric status and normative dissociative experiences. Arch Clin Neuropsychol 2010; 25: 39-48.
26. Cella D, Choi S, Garcia S, et al. Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. Qual Life Res 2014; 23: 2651-2661.
27. Cook KF, Victorson DE, Cella D, et al. Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers. Qual Life Res 2015; 24: 575-589.